Pharmacological exploration of dopamine hypersensitivity in migraine patients.
Patients with migraine show a hypersensitivity to dopamine or its agonists. One of these, piribedil, was administered as 0.1 mg/kg intravenously over 30 min to subjects with either migraine or other types of headache. This test provoked in migraine patients an increase of the cerebral blood flow and the peripheral signs of dopamine hypersensitivity:- nausea or vomiting and a rapid fall in blood pressure. In contrast, in those subjects with chronic non-migrainous headache, the administration of piribedil had no effect. The piribedil test appears to possess good specificity vis à vis migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migraine or psychogenic headache on clinical grounds alone.
D002560:Cerebrovascular Circulation / Q000187:drug effects; D004294:Domperidone / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D006261:Headache / Q000503:physiopathology; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008881:Migraine Disorders / Q000503:physiopathology*; D009325:Nausea / Q000139:chemically induced; D010879:Piperazines; D010891:Piribedil / Q000009:adverse effects; D013469:Sulpiride / Q000031:analogs & derivatives / Q000494:pharmacology
D010879:Piperazines; D004294:Domperidone; D013469:Sulpiride; C044421:RIV 2093; D010891:Piribedil; D004298:Dopamine